Franck Lescure

Aviwell operates at the convergence of DIGITAL & LIFE SCIENCES. Our mission is to develop natural and sustainable solutions to improve animal health to better nourish and provide FOOD SECURITY to the nearly 8 billion people on our planet ... And to do so a fraction of the cost. We are a deep-tech startup with our HQ in Toulouse, France and with sales offices in Boston, USA. The company is based on three disruptive assets: • Proprietary biostatistical algorithms, • Extensive microbiology and physiology expertise, and • Native and Adaptive Biomimicry When combined, we are able to develop revolutionary feed solutions for farmers that significantly improve animal growth and health. Aviwell aims to market these unique products on a global market.

Pili, carbon conscious color company By proposing renewable colors from the edge of biotechnology and organic chemistry, PILI is tackling the problem of color industry pollution. We take part in a long-term revolution regarding the way we produce, use and recycle products. This new era will be partly ruled by microorganisms that can be cultivated to produce a wide variety of renewable materials at industrial scale. This technology has been used for ages, mostly in the food industry through fermentation (beer, bread, cheese, chocolate, vinegar..) and more recently in health care, where engineered microorganisms produce pharmaceutical molecules (such as insuline), these champions now show up again in the production of smart and renewable materials. PILI is focused on the biofabrication of a wide range of colors produced by microorganisms as an alternative to the petrochemical versions (non-renewable, toxic to work with..) and without the drawbacks of the vegetal ones (non scalable, expensive, dependant on weather..). A lot of industrial sectors have been waiting for such a product and they are now cooperating with us, eager to use our living colors, from textile to plastic factories, in order to develop the future of colors in which we can already predict that affordable and sustainable products will lead the way! Our team at PILI is composed of sucessful scientists and engineers, experts in the fields of synthetic biology, bioproduction, chemistry and design. We are now working in two French-based laboratories : at Toulouse White Biotechnologies (South of France), where we bioengineer our microorganisms, and Le CNAM in Paris, where we develop sustainable synthesis and extraction methodologies and we test the properties of our biobased dyes and pigments.

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

Flash Therapeutics is a gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform and bioproduction technologies. The Company is built around the Vectalys lentiviral platform, which includes its patented non-integrative LentiFlash® technology, and integrative lentiviral vectors. By providing efficient, transient and short-term RNA delivery technology, LentiFlash® is suitable for gene editing and other advanced therapeutic approaches. When stable DNA expression is needed (e.g. immunotherapy such as CAR T cells), integrative lentiviral vectors will be the delivery method of choice. Both technologies benefit from novel production and purification processes developed and continually optimized since 2005. Flash Therapeutics was established in 2018 through the merger of FlashCell, a privately held company developing LentiFlash®, based RNA therapeutics; and Vectalys, a leading privately held 13-year old lentiviral vector manufacturer.

EnobraQ is a French start up developing fermentation processes to transform CO2 into commodity chemicals through synthetic biology

Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human cells. Antimicrobial resistant bacteria or AMR are responsible for over 700,000 death a year in 2014 according to the WHO. This number might reach over 10,000,000 by 2050 if nothing is done, and no new class of antibiotics has been discovered in the last 30 years. Phages represent one of the most promising approach to fight these AMR infections. Pherecydes Pharma has introduced the concept of precision phagotherapy, which consists in treating each patient according to the activity of the phages on the bacterial strain responsible for the infection. Treatments are therefore individualized and adapted to each case. Pherecydes Pharma has selected as priority bacterial targets Staphylococcus aureus, Pseudomonas aeruguinosa and Escherichia coli, that have been identified by the WHO among the most dangerous infections. These three bacteria alone account for the vast majority of nosocomial infections in industrialized countries, and as much as over 2/3rd of hospital resistant infections in France according to a recent study. Some of the patented phages developed by Pherecydes Pharma have already been administered as part of compassionate treatments in France under the supervision of French Health authorities (ANSM).

Founded in 2009 and based in Toulouse (France), Pylote is committed to green industrial mineral and ceramic chemistry. Pylote conceives and products innovative unique green mineral microspheres that can be integrated into numerous consumers’ products, through an exclusive in-house manufacturing process. Pylote’s industrial innovative technologies have a major competitive advantage as they make the end products smarter, by giving new and specific attributes to materials, with no change to the existing manufacturing process. Through a complete industrial offer and a licensed commercial model, Pylote brings added value to its clients, who are present in pharmaceutical, cosmetic, food or industrial markets, by proposing end consumers with greener, cleaner and safer products. For more information about Pylote www.pylote.com

Founded in 2010, Amoéba is an innovative industrial greentech specialised in the treatment of microbiological risk of natural resources. Our biosolutions are based on a unique micro-organism, the amoeba Willaertia magna C2c Maky. Thanks to our scientific, industrial and commercial know-how, we are able to provide biological alternatives for different applications and industries. 𝙊𝙐𝙍 𝙎𝙊𝙇𝙐𝙏𝙄𝙊𝙉𝙎 💄 Cosmetics : Our latest innovation offers anti-aging and UV protection properties. In October 2023, in vitro studies showed that this lysate stimulates cellular functions, activates wound healing genes, promotes hyaluronic acid synthesis, and enhances anti-infective immunity. These benefits were confirmed in a spring 2024 clinical study, with statistically significant results. Amoéba has successfully registered this ingredient on the INCI list, facilitating its commercialization and establishing it as a key player in innovative skincare solutions. 🌱 Biocontrol "AXPERA": Our second technology enables plant protection in agriculture and is based on the antifungal properties of the amoeba in its lysed (non-living) form. In 2022, the US Environmental Protection Agency (US EPA) has granted approval for the use of our solution in agriculture in the USA. In the same year, Austria issued a positive recommendation for the approval of our active substance in Europe. With this innovation, Amoéba contributes to an efficient, secure and more virtuous biological agriculture. 💧 Biocide "BIOMEBA": This historical application, initiated at the foundation of the company, enables the treatment of water in cooling towers and uses the amoeba Willaertia magna C2c Maky in its living form. In 2022, the US EPA has approved the use of our active substance in closed cooling systems in the USA, making our solution the first biological biocide approved for global industrial water treatment. Youtube 👉 @AmoebaNature X 👉 @AmoebaNature

Fab’entech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease. After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.

CYTOO is a preclinical stage drug discovery company specialized in muscular and neuromuscular disorders. CYTOO partners its versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates. CYOO has developed a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic). Core expertise lies on in vitro muscle regeneration, contraction, hypertrophy, and metabolism.

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).

TxCell is now a subsidiary of Sangamo Therapeutics, Inc. and has been renamed Sangamo Therapeutics France.

VC firm investing in European growth stage digital health companies. Led by the former Chief Strategy Officer of Sanofi & a digital health VC partner, KELES bridges the gap between start up innovation, international scaling and global impact. We are uniquely positioned to access the best deals, enable scale up and maximize exit opportunities. Weve sat at every seat around the table; from inception to exit to investor and acquirer, we know the economics and how-to of execution. €250m Fund - Ticket Size €8m to €30m KELES Investment Focus: Growth Stage - Demonstrated Profitability - Scaling Inflection Point 3 Core Digital Health Segments: New R&D Model (techbio/digitised trials) - Diagnostics (AI imaging/digital medtech) - Patient Care (acute/chronic) The fund KELES S.C.Sp., SICAV - RAIF is established in Luxembourg, and we have bases in Paris, London and Brussels.

Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms.

Aviwell operates at the convergence of DIGITAL & LIFE SCIENCES. Our mission is to develop natural and sustainable solutions to improve animal health to better nourish and provide FOOD SECURITY to the nearly 8 billion people on our planet ... And to do so a fraction of the cost. We are a deep-tech startup with our HQ in Toulouse, France and with sales offices in Boston, USA. The company is based on three disruptive assets: • Proprietary biostatistical algorithms, • Extensive microbiology and physiology expertise, and • Native and Adaptive Biomimicry When combined, we are able to develop revolutionary feed solutions for farmers that significantly improve animal growth and health. Aviwell aims to market these unique products on a global market.

Pili, carbon conscious color company By proposing renewable colors from the edge of biotechnology and organic chemistry, PILI is tackling the problem of color industry pollution. We take part in a long-term revolution regarding the way we produce, use and recycle products. This new era will be partly ruled by microorganisms that can be cultivated to produce a wide variety of renewable materials at industrial scale. This technology has been used for ages, mostly in the food industry through fermentation (beer, bread, cheese, chocolate, vinegar..) and more recently in health care, where engineered microorganisms produce pharmaceutical molecules (such as insuline), these champions now show up again in the production of smart and renewable materials. PILI is focused on the biofabrication of a wide range of colors produced by microorganisms as an alternative to the petrochemical versions (non-renewable, toxic to work with..) and without the drawbacks of the vegetal ones (non scalable, expensive, dependant on weather..). A lot of industrial sectors have been waiting for such a product and they are now cooperating with us, eager to use our living colors, from textile to plastic factories, in order to develop the future of colors in which we can already predict that affordable and sustainable products will lead the way! Our team at PILI is composed of sucessful scientists and engineers, experts in the fields of synthetic biology, bioproduction, chemistry and design. We are now working in two French-based laboratories : at Toulouse White Biotechnologies (South of France), where we bioengineer our microorganisms, and Le CNAM in Paris, where we develop sustainable synthesis and extraction methodologies and we test the properties of our biobased dyes and pigments.

Elaia is a full stack tech and deep tech investor. We partner with ambitious entrepreneurs from inception to leadership, helping them navigate the future and the unknown. For over twenty years, we have combined deep scientific and technological expertise with decades of operational experience to back those building tomorrow. Our joint venture with Lazard, Lazard Elaia Capital, enables us to support exceptional founders at any stage. From our offices in Paris, Barcelona and Tel Aviv, we have been active partners with over 100 startups including Criteo, Mirakl, Shift Technology, AQEMIA and Alice & Bob.